Objectives The purpose of this paper was to investigate the effects of dapagliflozin in chronic
kidney disease (CKD) patients, with and without heart failure (HF). Background Patients with …

Background: Dapagliflozin reduces the risk of end-stage renal disease in patients with
chronic kidney disease. We examined the relative risk of cardiovascular and renal events in …

Background The DAPA‐CKD (Dapagliflozin and Prevention of Adverse Outcomes in
Chronic Kidney Disease) trial (NCT03036150) demonstrated that dapagliflozin reduced the …

Background Dapagliflozin reduces the risk of kidney failure and heart failure in patients with
chronic kidney disease. We aimed to investigate the effects of dapagliflozin on kidney …

Aims Mortality rates from chronic kidney disease (CKD) have increased in the last decade. In
this pre-specified analysis of the DAPA-CKD trial, we determined the effects of dapagliflozin …

Abstract Aims/hypothesis In the Dapagliflozin and Prevention of Adverse Outcomes in
Chronic Kidney Disease (DAPA-CKD) trial, dapagliflozin reduced the risks of progressive …

Background Patients with chronic kidney disease have a high risk of adverse kidney and
cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease …

OBJECTIVE The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney
Disease (DAPA-CKD) study demonstrated risk reduction for kidney and cardiovascular …

Background In the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney
Disease (DAPA-CKD) randomized, placebo-controlled trial, the sodium-glucose …

Abstract Background The Dapagliflozin and Prevention of Adverse outcomes in Chronic
Kidney Disease (DAPA-CKD; NCT03036150) trial was designed to assess the effect of the …